Cefiderocol as a Treatment Option for Stenotrophomonas maltophilia Causing Hospital-Acquired/Ventilator-Associated Pneumonia

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 5; p. e38613
• Main Authors: Rashid, Muhammad Humayoun, Bukhari, Syeda Neelam Yamin, Mousa, Aliaa, Aziz, Ahmed Ali, Hakobyan, Knkush
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 05-05-2023; Cureus
• Subjects: Antibiotics; Bacteria; Bacterial infections; Blood; Case reports; Drug dosages; Drug resistance; FDA approval; Gram-negative bacteria; Hemodialysis; Hospitalization; Hospitals; Infectious Disease; Internal Medicine; Leukocytes; Mortality; Pathogens; Pneumonia; Urinary tract diseases; Urinary tract infections; Urogenital system; Ventilators; X-rays; cefiderocol; stenotophomonas maltophilia; ventilator-associated pneumonia; hospital-acquired pneumonia; multi-drug resistant bacteria
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.38613

Multidrug-resistant (MDR) gram-negative bacteria have been causing havoc for the healthcare system because of the rarity of the treatment options available. 
 is a non-fermenting gram-negative bacterium that causes different infections, particularly respiratory tract infections. It displays resistance to many antibiotics (e.g., carbapenems, fluoroquinolones, and trimethoprim-sulfamethoxazole). Cefiderocol is a novel antibiotic which still in the preclinical stages of Food and Drug Administration (FDA) approval for
. We present the case of a 76-year-old male with end-stage renal disease (ESRD), intubated for acute hypoxemic respiratory failure due to volume overload and worsening oxygenation, who subsequently developed ventilator-associated pneumonia, found to be due to MDR S
The patient ultimately showed clinical improvement with a 7-day course with a renally adjusted dose of cefiderocol. This shows that cefiderocol can prove to be a potential treatment option against serious infections caused by difficult-to-treat